Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBITDA: 2012-2025

Historic EBITDA for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to $22.9 million.

  • Veracyte's EBITDA rose 90.95% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year increase of 205.17%. This contributed to the annual value of $16.1 million for FY2024, which is 118.81% up from last year.
  • Veracyte's EBITDA amounted to $22.9 million in Q3 2025, which was up 535.57% from -$5.3 million recorded in Q2 2025.
  • Veracyte's 5-year EBITDA high stood at $22.9 million for Q3 2025, and its period low was -$41.9 million during Q1 2021.
  • In the last 3 years, Veracyte's EBITDA had a median value of -$4.7 million in 2024 and averaged -$4.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 555.11% in 2023, then surged by 162.37% in 2025.
  • Over the past 5 years, Veracyte's EBITDA (Quarterly) stood at -$12.3 million in 2021, then skyrocketed by 56.05% to -$5.4 million in 2022, then crashed by 555.11% to -$35.5 million in 2023, then spiked by 111.76% to $4.2 million in 2024, then skyrocketed by 90.95% to $22.9 million in 2025.
  • Its EBITDA stands at $22.9 million for Q3 2025, versus -$5.3 million for Q2 2025 and $2.9 million for Q1 2025.